• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

价值观如何塑造技术设计?对学术衍生企业中追求健康和财富合法化因素的探索。

How do values shape technology design? An exploration of what makes the pursuit of health and wealth legitimate in academic spin-offs.

作者信息

Lehoux Pascale, Daudelin Geneviève, Hivon Myriam, Miller Fiona Alice, Denis Jean-Louis

机构信息

Department of Health Administration, University of Montreal, France; Institute of Public Health Research, University of Montreal, France.

出版信息

Sociol Health Illn. 2014 Jun;36(5):738-55. doi: 10.1111/1467-9566.12097. Epub 2014 Jan 21.

DOI:10.1111/1467-9566.12097
PMID:24444436
Abstract

By actively supporting cooperation between academia, clinical settings and industry, several policy initiatives assume that the two policy agendas of health and wealth can be reconciled through the development of health technology. Our goal in this article is to shed light on the way the concurrent pursuit of health and wealth operates in practice by examining the valuation schemes, actions and decisions that shaped technology development in three Canadian spin-offs. Drawing on the sociology of judgement, our analytical framework conceives of technology development as a purposive collective action that unfolds in a normatively heterogeneous context (one pervaded with both corporate and public service mission values and norms). Our qualitative empirical analyses explore four valuation schemes and their corresponding regimes of engagement that characterise why and how technology developers commit themselves to addressing certain clinical, interactional, organisational and economic concerns throughout the development process. Our discussion suggests that the ability to reconcile health and wealth goals is to be found in the moral repertoires that provide meaning to, and render coherent technology developers' participation in corporate activities driven by economic growth.

摘要

通过积极支持学术界、临床机构和产业界之间的合作,一些政策倡议认为,健康与财富这两个政策议程可以通过健康技术的发展得以协调。本文的目标是,通过考察塑造了三家加拿大衍生公司技术发展的评估方案、行动和决策,来揭示在实践中同时追求健康与财富的方式。借鉴判断社会学,我们的分析框架将技术发展视为一种有目的的集体行动,它在一个规范异质的背景中展开(一个同时充斥着企业和公共服务使命价值观及规范的背景)。我们的定性实证分析探究了四种评估方案及其相应的参与机制,这些机制刻画了技术开发者在整个开发过程中致力于解决某些临床、互动、组织和经济问题的原因及方式。我们的讨论表明,协调健康与财富目标的能力存在于道德准则之中,这些道德准则为技术开发者参与由经济增长驱动的企业活动赋予意义并使其具有连贯性。

相似文献

1
How do values shape technology design? An exploration of what makes the pursuit of health and wealth legitimate in academic spin-offs.价值观如何塑造技术设计?对学术衍生企业中追求健康和财富合法化因素的探索。
Sociol Health Illn. 2014 Jun;36(5):738-55. doi: 10.1111/1467-9566.12097. Epub 2014 Jan 21.
2
Ethical implications of for-profit corporate sponsorship of research.营利性企业对研究的赞助所涉及的伦理问题。
SRA J. 1990 Summer;22(1):23-7.
3
Paradox, process and perception: the role of organizations in clinical practice guidelines development.悖论、过程与认知:组织在临床实践指南制定中的作用
CMAJ. 1995 Oct 15;153(8):1073-7.
4
Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.为新医疗技术创造价值:企业家、投资者和监管机构的早期贡献。
Int J Health Policy Manag. 2017 Sep 1;6(9):509-518. doi: 10.15171/ijhpm.2017.11.
5
Translational science and the hidden research system in universities and academic hospitals: a case study.转化科学与大学和学术医院中的隐性研究系统:一项案例研究。
Soc Sci Med. 2011 Feb;72(4):537-44. doi: 10.1016/j.socscimed.2010.11.019. Epub 2010 Nov 27.
6
Risk management frameworks for human health and environmental risks.人类健康与环境风险的风险管理框架。
J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608.
7
Imagining value, imagining users: academic technology transfer for health innovation.
Soc Sci Med. 2009 Apr;68(8):1481-8. doi: 10.1016/j.socscimed.2009.01.043. Epub 2009 Feb 21.
8
Institutional academic industry relationship: results of interviews with university leaders.机构的学术与行业关系:对大学领导的访谈结果
Account Res. 2004 Apr-Jun;11(2):103-18. doi: 10.1080/03050620490512296.
9
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
10
University spin-offs: opportunity or challenge?大学衍生企业:机遇还是挑战?
Nat Mater. 2006 Dec;5(12):923-5. doi: 10.1038/nmat1790.

引用本文的文献

1
Legitimacy as Social Infrastructure: A Critical Interpretive Synthesis of the Literature on Legitimacy in Health and Technology.作为社会基础设施的合法性:对健康与技术领域合法性文献的批判性解释性综述
JMIR Hum Factors. 2025 Mar 5;12:e48955. doi: 10.2196/48955.
2
Values of welfare technologies: a qualitative study of how employees in Swedish care for older adults understand and justify the use of new technology.福利技术的价值:关于瑞典老年护理员工如何理解和论证新技术使用情况的定性研究。
BMC Health Serv Res. 2024 Dec 6;24(1):1555. doi: 10.1186/s12913-024-12053-1.
3
Why is repositioning public health innovation towards a social paradigm necessary? A reflection on the field of public health through the examples of Ebola and Covid-19.
为什么需要将公共卫生创新重新定位为社会范式?通过埃博拉和新冠疫情这两个例子对公共卫生领域进行反思。
Global Health. 2021 Apr 14;17(1):46. doi: 10.1186/s12992-021-00695-3.
4
The institutional workers of biomedical science: Legitimizing academic entrepreneurship and obscuring conflicts of interest.生物医学科学领域的机构工作人员:使学术创业合法化并掩盖利益冲突。
Sci Public Policy. 2018 Jun;45(3):404-415. doi: 10.1093/scipol/scx075. Epub 2017 Nov 6.
5
The Bright Elusive Butterfly of Value in Health Technology Development Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".卫生技术开发中价值的光明 elusive 蝴蝶——评“为新卫生技术提供价值:企业家、投资者和监管机构的早期贡献”
Int J Health Policy Manag. 2018 Jan 1;7(1):81-85. doi: 10.15171/ijhpm.2017.65.
6
Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.为新医疗技术创造价值:企业家、投资者和监管机构的早期贡献。
Int J Health Policy Manag. 2017 Sep 1;6(9):509-518. doi: 10.15171/ijhpm.2017.11.
7
How does venture capital operate in medical innovation?风险投资在医学创新中是如何运作的?
BMJ Innov. 2016 Jul;2(3):111-117. doi: 10.1136/bmjinnov-2015-000079. Epub 2016 Apr 15.